MTOR and head and neck squamous cell carcinoma: For instance, afatinib, which contains a quinazoline heterocycle, has demonstrated anti-cancer efficacy in head and neck squamous cell carcinoma (HNSCC) by inhibiting the mammalian target of rapamycin (mTORC1), leading to apoptosis in cancer cells [36].